In a phase Ib study, greater than 90% of prasugrel-treated patients achieved greater than 20% inhibition of platelet aggregation, compared with less than 50% of Plavix treated patients.
The study showed that even patients with more reactive platelets at baseline, a population whose platelets may be less affected or unaffected by current thienopyridine therapies, have higher and more consistent inhibition of platelet aggregation with prasugrel than with Plavix.
“Certain patients have more reactive platelets that are less affected or unaffected by current thienopyridines, so it is very encouraging to see in this study how well the platelets of those who were dosed with prasugrel responded, regardless of baseline platelet reactivity,” said Dr Joseph Jakubowski, research fellow, Eli Lilly and Company.